Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Helix BioPharma Corp.TSX: HBP.TO
Property, Plant & Equipment (Net) · Q3 FY2026 · quarter ended Apr 2026
Property, plant & equipment (net) falls 85.7% from a year ago
Property, plant & equipment (net) stood at CA$1K at the end of Q3 FY2026, down 85.7% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -51.5% a year.
Context
- Property, plant & equipment (net) amounted to 0.0% of total assets at the end of Q3 FY2026, down 0.7 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -85.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
CAD · from the balance sheet
- Latest · FY2025
- 4K CAD
- Year-over-year change
- -87.9%
- 4-year CAGR
- -46.0%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 4K | -87.9% |
| FY2024 | 2024-07-31 | 33K | +0.0% |
| FY2023 | 2023-07-31 | 33K | -5.7% |
| FY2022 | 2022-07-31 | 35K | -25.5% |
| FY2021 | 2021-07-31 | 47K | — |
Property, Plant & Equipment (Net) vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -85.7% is the 4th highest of 5, against a peer median of -1.5%.
- Property, plant & equipment (net) amounts to 0.0% of total assets for HBP.TO, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.17M USD | +20.9% | +5.8% | 0.9% | |
| Mar 2026 | CA$138.97K CAD | -23.9% | -26.4% | 0.4% | |
| Apr 2026 | CA$8.86K CAD | -98.8% | -70.0% | 0.6% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $8.01K USD | +166.8% | -17.8% | 0.0% |
| Apr 2026 | CA$1K CAD | -85.7% | -51.5% | 0.0% | |
| Peer median (excluding HBP.TO) | — | -1.5% | -22.1% | 0.5% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.